4.71% 0.0008

Galera Therapeutics Inc (GRTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt GRTX? Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Galera Therapeutics Inc Stock (GRTX) Company Profile

Galera Therapeutics Inc

Healthcare (1150)

Biotechnology (644)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

GRTX's Discussions on Twitter

Vergleichen Sie GRTX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GRTX Galera Therapeutics Inc	0.0178	0	0	-69.68M	-48.93M	-1.89
VRTX Vertex Pharmaceuticals Inc	391.36	100.82B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	461.24	60.45B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	575.06	60.69B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	752.32	46.32B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	327.20	36.58B	3.81B	-644.79M	-669.77M	-6.24

Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-08-10	Herabstufung	Piper Sandler	Overweight → Neutral
2021-10-19	Herabstufung	BTIG Research	Buy → Neutral
2021-10-19	Herabstufung	BofA Securities	Buy → Underperform
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2020-12-16	Hochstufung	Credit Suisse	Neutral → Outperform
2020-12-07	Eingeleitet	H.C. Wainwright	Buy
2019-12-02	Eingeleitet	BTIG Research	Buy
2019-12-02	Eingeleitet	BofA/Merrill	Buy
2019-12-02	Eingeleitet	Citigroup	Buy
2019-12-02	Eingeleitet	Credit Suisse	Neutral

Alle ansehen

Galera Therapeutics Inc Aktie (GRTX) Neueste Nachrichten

Finanzdaten der Galera Therapeutics Inc-Aktie (GRTX)

Galera Therapeutics Inc (GRTX)

Galera Therapeutics Inc Stock (GRTX) Company Profile

Vergleichen Sie GRTX mit anderen Aktien

Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades

Galera Therapeutics Inc Aktie (GRTX) Neueste Nachrichten

North American Morning Briefing : Stock Futures -2- - MarketScreener

Oral Mucositis Market Growth, Trends, Consumer Demand and Key Opportunities - openPR.com

Galera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener

Galera Therapeutics, Inc. SEC 10-Q Report - TradingView

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Lelezard

Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - The Manila Times

Oral Mucositis Treatment Market 2034: EMA, PDMA, FDA Approvals, - openPR.com

Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com

U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com

Radiation-induced Esophagitis Treatment Market Size in 7MM - openPR.com

Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire

Galera Therapeutics extends agreement deadline - Investing.com Australia

Galera Therapeutics extends agreement deadline By Investing.com - Investing.com South Africa

Galera Therapeutics Inc. (GRTX) reports earnings - Quartz

Radiotherapy Induced Oral Mucositis Treatment Market Size - openPR.com

Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights

Galera Therapeutics holds annual stockholder meeting - Investing.com

Oral Mucositis Treatment Market Size to Hit USD 3.72 Billion by 2034 - Precedence Research

Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - VISTA.Today

Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech

Galera Therapeutics completes acquisition of Nova Pharmaceuticals - Nasdaq

FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace

Twelve option delistings on December 23rd - TipRanks

Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA Today

The 2024 Biotech Graveyard - Fierce Biotech

Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart.com

Galera stockholders reject liquidation plan - Investing.com

UroGen Appoints Chris Degnan as Chief Financial Officer - Yahoo Finance

2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech

Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda - GlobeNewswire

Galera Therapeutics faces Nasdaq delisting - Investing.com

"Trimming the Fat or Losing the Muscle? August 2024’s Biotech Layoff Frenzy Signals Strategic 'Adjustments' in the Name of Efficiency" - BioSpectrum Asia

Galera Therapeutics Announces Plan of Liquidation and Dissolution Amid Financial Updates - MyChesCo

Galera Announces Board Approval of Complete Liquidation and Dissolution - GlobeNewswire

Galera Therapeutics settles lawsuit for $975,000 - Investing.com

Biopharma layoff tracker 2023: Atreca, Galera, INOVIO and more cut staff - PharmaLive

Why Galera Therapeutics (GRTX) Stock Is Nosediving - TradingView

Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics - Hunt Scanlon Media

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire

Galera Therapeutics Enacts Plan to Deter Hostile Takeovers - TipRanks

Galera Therapeutics Implements Stockholder Rights Plan to Shield Investor Interests - MyChesCo

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer - PR Newswire

Oral Mucositis Treatment Market Size & Share Report, 2032 - Global Market Insights

Radiotherapy Induced Oral Mucositis Treatment Market, 2032 - Global Market Insights

Opthalmic Industry Veteran Joins Nacuity Pharmaceuticals’ Board - Dallas Innovates

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates - Yahoo Finance

Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying - TradingView

2023 gainers and losers: Positive trial outcomes and M&As propel biopharma stocks to strong finish - BioWorld MedTech

Galera Announces Receipt of Type A Meeting Minutes and Strategic Update - Yahoo Finance

Finanzdaten der Galera Therapeutics Inc-Aktie (GRTX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie GRTX